Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Ovarian Neoplasms 10Recurrence 9Neoplasms 9Small Cell Lung Carcinoma 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma 5Multiple Myeloma 4Lymphoma, Follicular 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Mesothelioma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Kidney Neoplasms 3

Interventions

Cisplatin 7Cetuximab 6Radiotherapy, Intensity-Modulated 4pembrolizumab 3durvalumab 3Radiotherapy 2Radiation 2Observation 2Drug Therapy 2Celecoxib 2Bupropion 2130-nm albumin-bound paclitaxel 2trametinib 1sodium thiosulfate 1gluconic acid 1ficlatuzumab 1Zinc 1Watchful Waiting 1Varenicline 1Transcutaneous Electric Nerve Stimulation 1Tobacco Use Cessation Devices 1Tadalafil 1Sirolimus 1RRx-001 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Pilocarpine 1Photochemotherapy 1Periodontal Debridement 1Oral Hygiene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Mouth Neoplasms × durvalumab × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
39 enrolled 8 charts
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
18 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡